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INTRODUCTION
ASA (acetylsalicylic acid, or aspirin) hypersensitivity is
usually classified into two clinical types: asthma and urticaria
with or without angioedema. Although the two manifesta-
tions are combined in some patients, ASA-induced urticaria/
angioedema (AIU) may affect a different subpopulation from
ASA-intolerant asthma (AIA) (1). The prevalence of AIU is
approximately 0.3% of the normal population (2) and urticaria
symptoms can be aggravated by ASA and other nonsteroidal
anti-inflammatory drugs (NSAIDs) in one third of patients
with chronic urticaria (3). It has been reported that urinary
methylhistamine is increased in chronic urticaria patients
with ASA hypersensitivity after ASA provocation test (4).
The mechanism of ASA hypersensitivity in cutaneous reac-
tion remain largely unknown, but the key cell in urticaria is
mast cell, histamine is a key mediator in the urticaria and its
clinical symptoms (erythma, angioedema, itching) can be con-
trolled by antihistamines.
Considering the pathogenic mechanisms of AIU, we can
speculate that the polymorphisms of candidate genes involved
in histamine release and metabolism and its receptors (H1
and H2 receptors) may be associated with the AIU pheno-
type. To release histamine from mast cells, the key step is a
cross-linking of allergens with IgE, which is bound with the
high-affinity IgE receptor (FCER1B) located on their surface
(5). Histamine release via autoantibodies against FCER1B
was noted in the pathogenic mechanism of chronic idiopathic
urticaria (6, 7). Several investigators demonstrated a positive
association of gene polymorphism of the  chain of FCER1B
with high serum total IgE level, atopy or the asthma pheno-
type (8-11). Histamine is metabolized primarily by histamine
N-methyltransferase (HNMT) and diamine oxidase (5). In
addition, the effects of histamine are mediated through two
types of receptors: the histamine H1 receptor (HRH1) and
the histamine H2 receptor (HRH2). HNMT 314C>T, result-
ing in a T105I amino acid change, has been shown to induce
a functional difference in enzyme activity (12).
In this study, we analyzed eleven known single nucleotide poly-
morphisms (SNPs) of the FCER1B, HNMT, HRH1, HRH2
and their haplotypes in AIU patients, compared with other
drug allergy patients presenting as exanthematous skin symp-
toms, and in normal healthy controls in a Korean population.
MATERIALS AND METHODS
Subjects 
110 patients with AIU, 53 patients having no ASA hyper-
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Polymorphisms of High-Affinity IgE Receptor and Histamine-Related
Genes in Patients with ASA-Induced Urticaria/Angioedema 
The pathogenic mechanism of ASA-induced urticaria/angioedema (AIU) is still poorly
understood, but it has been known that histamine releasing by cutaneous mast cell
activation is considered to be an important role. Considering the importance of his-
tamine in AIU, we speculated that a genetic abnormality of histamine-related genes
such as a high-affinity IgE receptor, a metabolic enzyme of histamines and histamine
receptors, may be involved in the development of AIU. Enrolled in the study were
110 patients with AIU, 53 patients without ASA hypersensitivity who had various
drug allergies presenting as exanthematous skin symptoms, and 99 normal healthy
controls (NC). Eleven single nucleotide polymorphisms (SNPs) of the  chain of the
high-affinity IgE receptor (FCER1B) and three histamine-related genes-histamine
N-methyltransferase (HNMT), histamine H1 receptor (HRH1), histamine H2 receptor
(HRH2)-were screened using the SNP-IT assay based on a single base extension
method. No significant differences were observed in allele and genotype frequen-
cies, and haplotype frequencies of all the SNPs of FCER1B, HNMT, HRH1, and
HRH2 among the three groups (p>0.05, respectively). These results suggest that
the polymorphisms of FCER1B and the three histamine-related genes may not con-
tribute to the development of AIU phenotype in the Korean population. 
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sensitivity with various drug allergies presenting as skin man-
ifestations (especially maculopapular exanthematus rash), and
99 normal healthy controls were enrolled by the Department
of Allergy and Rheumatology, Ajou University Hospital,
located in the Republic of Korea. All the subjects were Korean.
The phenotype of AIU was defined as those having positive
results on an ASA oral provocation test, which was performed
with 500 mg of ASA (Rhonal
�, KunWha Pharmaceutical
Co., Seoul, Korea). Patients having ASA intolerant asthma
and AIU were excluded. Normal controls, who had non-atopy,
no personal and family history of allergic diseases, and no
past history of ASA and other drug hypersensitivity, were
recruited from the general population. All subjects gave
informed consent, which was then approved by the local eth-
ical committee. Skin prick tests were performed with 12 com-
mon aeroallergens (Bencard Co., Bredford, U.K.). Atopy was
defined as one or more positive reactions to the skin prick
test. Chronic urticaria was defined as the daily or near-daily
presence of itchy wheals for more than 6 weeks.
SNP genotyping for allele frequencies of the candidate
genes
Single nucleotide polymorphism (SNP) genotyping was
performed by SNP-ITTM assays using the SNPstream 25KTM
System (Orchid Biosciences, New Jersey, U.S.A.). Briefly, the
genomic DNA region spanning the polymorphic site was
amplified using one phosphothiolated primer and one regu-
lar PCR primer (Table 1). The amplified PCR products were
digested with exonucleases. The 5′ phosphthiolates protected
one strand of the PCR product from exonuclease digestion,
resulting in the generation of a single-stranded PCR template.
The single-stranded PCR template was overlaid onto a 384
well plate containing a covalently attached SNP-ITTM primer
extension primer designed to hybridize immediately adjacent
to the polymorphic site. The SNP-ITTM primer was extend-
ed for a single base with a DNA polymerase and mixture of
an appropriate acycloterminator, which was labeled with either
FITC or biotin and complementary to the polymorphic nu-
cleotide. The identity of the incorporated nucleotide was deter-
mined with serial colorimetric reactions with anti-FITC-AP
and streptavidin-HRP, respectively. The results of yellow and/
or blue color developments were analyzed with the ELISA
reader and the final genotype calls were made with the QCR-
eviewTM program.
Statistical analysis
The differences of clinical characteristics between two groups
were determined by Student’s t-test for continuous variables
and chi-square test for categorical variables. The Hardy-Wein-
berg equilibrium was estimated by chi-square tests. The hap-
lotypes of FCER1B and HNMT were analyzed with the Hap-
lotyper program based on the Bayesian algorithm (13), and
linkage disequilibrium between loci were measured using
Lewontin’s |D′ | (14). Logistic regression models were used for
analysis of allele and haplotype frequencies controlling age,
sex and atopy as co-variables with alternative models (co-domi-
Gene Locus Position Primers
FCER1B -109 T>C Promoter For/Rev AAAATTATGCTCCAGGAGTCTCA/ATAAGTTTCTTGGCTGATTAAGATCA
(11q23) Extension TTTACTTGTGATGAATAGAAAAATT
RsaI_Int2 Intron2 For/Rev AAGGATTCATAATCTTTATCTTTACTTAGATG/TAATGCATGGAAGGCCAA
Extension ACTTTTCTCCATGCGCCTTTATGTA
I181L(A>C) Exon6 For/Rev TCTTTTTGTTTGTCATTTGTTGC/TTGTTTCCTTTGAGTTCTTCCC
Extension GTGAGAAACAGCATCATCACTACAA
E237G(A>G) Exon7 For/Rev AGAGGATCGTGTTTATGAAGAATTAAAC/GAATCAGAGTGTTCTGGACACGT
Extension CTTACAGTGAGTTGGAAGACXCAGGGG
RsaI_Ex7 Exon7 For/Rev TTTTCTCAAGATCATTCTGAGAGTT/AAGAGAACCCCAGCATTGT
Extension TGTGCTCTGTGTCTGXCTGAGGTGGGC
HNMT 939A>G 3'UTR For/Rev AGGCATAACTATCAATCACAAAAGTATA/TTTATCTACATTAATGGATGAGTTTGTG
(2q22.1) Extension TGAGTTTGTGATTTTAATATGGAAA
T105I(C>T) Exon4 For/Rev ATGGTGTGTCACCTCTTCT/ATGTCTCCTTATGCCAAGCA
Extension TCTGTATTTTAGAGCTXGTAGCCAAGA
HRH1 -17C>T Promoter For/Rev TGATGAACATCATGCTACTAAGTG/TTCTAAGAGGCAGGAGGAATT
(3p25) Extension GGGAGXCTCATTGXCGCAAGAGCAGCC
D349N(G>A) Exon3 For/Rev TCAAGACAGATGAGCAGGG/TCTGTGGTGGTATCTGAGTCC
Extension AGGATTGGCTAXCACCTAACATCTGAT
HRH2 543G>A Exon1 For/Rev AGGGCAATCATACCACCTCT/GTAGCGGGAGGTAGAAGGTG
(5q35.3) Extension TGACCAGCCCATCCACCAGCCCGTA
826C>T Exon1 For/Rev GCTGAGAGGGGATGATGC/AAGTCTCTGTTCAGCGCAG
Extension GGTTCAGGXXTGAGTTGGCATAGCCCA
Table 1. Amplifying and extension primers of the candidate genes
For/Rev, forward/reverse amplifying primers; E, glutamate; G, glycine; I, isoleucine; L, leucine; T, threonine; D, aspartate; N, asparagine.Polymorphisms of High-Affinity IgE Receptor and Histamine-Related Genes 369
nant, dominant and recessive models). P values were corrected
for multiple comparisons with the pairs of groups of interest
using the Bonferroni method (15). A p value of 0.05 or less
was regarded as significant. All statistical analyses were per-
formed using the software SPSS, version 10.0 (Chicago, IL,
U.S.A.).
RESULTS
The clinical characteristics of the study subjects 
The clinical characteristics of the study subjects are sum-
marized in Table 2. Significant differences existed in the mean
age between the patients with other drug allergies and the
other two groups (p<0.05, respectively). The prevalence of
atopy was 78.6% in AIU patients and 55.5% in patients with
other drug allergies, indicating a significant difference (p<
Gene Loci AIU (n=110) NC (n=99)
p value*
AIU vs. other AIU vs. NC
Other drug allergy
(n=53)
FCER1B -109T>C TT 53 (48.6%) 23 (43.4%) 46 (46.5%)
CT 46 (42.2%) 24 (45.3%) 43 (43.4%) NS
CC 10 (9.2%) 6 (11.3%) 10 (10.1%)
allele freq 0.3 0.34 0.32 0.278 0.673
RsaI_in2 G>A GG 73 (66.4%) 35 (66.0%) 69 (70.4%)
GA 32 (29.1%) 13 (24.5%) 26 (26.5%) NS
AA 5 (4.5%) 5 (9.4%) 3 (3.1%)
allele freq 0.19 0.22 0.16 0.482 0.466
E237G*(A>G) AA 86 (78.2%) 40 (75.5%) 70 (70.7%)
GA 23 (20.9%) 12 (22.6%) 27 (27.3%) NS
GG 1 (0.9%) 1 (1.9%) 2 (2.0%)
allele freq 0.11 0.13 0.16 0.386 0.162
RsaI_ex7 T>C TT 99 (90.0%) 44 (84.6%) 89 (90.8%)
CT 9 (8.2%) 8 (15.4%) 8 (8.2%) NS
CC 2 (1.8%) 0 1 (1.0%)
allele freq 0.06 0.08 0.05 0.354 0.678
HNMT T105 I*(C>T) CC 100 (90.9%) 50 (94.3%) 89 (89.9%)
CT 10 (9.1%) 3 (5.7%) 10 (10.1%) NS
TT 0 0 0
allele freq 0.05 0.03 0.05 0.453 0.857
939A>G AA 61 (56.0%) 26 (50.0%) 48 (49.0%)
AG 41 (37.6%) 21 (40.4%) 39 (39.8%) NS
GG 7 (6.4%) 5 (9.6%) 11 (11.2%)
allele freq 0.25 0.3 0.31 0.54 0.196
HRH1 -17C>T CC 97 (89.8%) 47 (92.2%) 89 (90.8%)
CT 11 (10.2%) 4 (7.8%) 9 (9.2%) NS
TT 0 0 0
allele freq 0.05 0.04 0.05 0.714 0.858
HRH2 543G>A GG 100 (91.7%) 48 (92.3%) 83 (83.8%)
AG 9 (8.3%) 4 (7.7%) 16 (16.2%) NS
AA 0 0 0
allele freq 0.04 0.04 0.08 0.824 0.098
Table 3. The allele and genotype frequencies of the SNPs in the candidate genes 
*Each p value was calculated with co-dominant, dominant and recessive models. Logistic regression analysis was applied to control for age, sex atopy
as covariables. E, glutamate; G, glycine; T, threonine; I, isoleucine; AIU, ASA-induced urticaria/angioedema; NS, non significant.
AIU 
(n=110)
NC 
(n=99)
p
value
Other drug 
allergy (n=53)
Age (yr) 34.9±12.5 42.1±17.0 36.3±14.2 <0.05
Sex (M) 49 (44.5%) 22 (41.5%) 44 (44.4%) NS
Atopy 77 (78.6%) 20 (55.5%) 0 <0.05
History of  9 (8.1%) 2 (1.8%) NA NS
other drug allergy
History of  56 (50.9%) 6 (11.3%) NA <0.01
allergic diseases
Chronic urticaria 33 (33.8%) 3 (5.7%) NA <0.01
Urticaria 45 (40.9%) 7 (13.2%) NA
Angioedema 17 (15.5%) 4 (7.5%) NA
Urticaria/Angioedema 44 (40.0%) 2 (3.8%) NA
MPE 0 28 (52.8%) NA
Anaphylaxis 4 (3.6%) 9 (17.0%) NA
Table 2. Clinical characteristics of the study subjects
AIU, ASA-induced urticaria/angioedema; MPE, maculopapular exanthe-
matous rash; NC, normal control; NA, non applicable; NS, non significant.370 J.-H. Choi, S.-H. Kim, C-H. Suh, et al.
0.05). Furthermore, significant differences were found in the
prevalence of allergic diseases (including bronchial asthma,
allergic rhinitis, allergic conjunctivitis, atopic dermatitis and
food allergies) between AIU patients (50.9%) and patients
with other drug allergies (11.3%, p<0.01). Thirty three of
AIU patients (33.8%) had chronic urticaria.
Genotype and allele frequencies of the target genes
Genotype distributions of all loci were in the Hardy-Wein-
berg equilibrium (p>0.05). Allele and genotype frequencies
of each SNP of the four candidate genes are shown in Table 3.
The frequency of variant allele was extremely low in FCER1B
I181L (q=0), HRH1 D349N (q=0) and HRH2 826C>T
(q=0.003), being excluded from the statistical analysis. No
significant differences were found in allele and genotype fre-
quencies among the three groups with alternative models (co-
dominant, dominant and recessive models). When clinical
parameters were analyzed according to the genotypes, serum
total IgE levels in AIU patients with FCER1B G237 allele
(n=22, 176.2±239.4 IU/mL) was significantly lower than
those with the E237 variant (n=79, 374.1±375.0 IU/mL,
p=0.004, data not shown). However, no significant differ-
ences were observed in atopy rate and serum total IgE level
according to the genotypes of the other genes studied (data
not shown).
Haplotype frequencies of the target genes
There were four haplotypes in FCER1B having frequencies
of more than 1% among the seven haplotypes observed, and
three haplotypes in HNMT (Table 4). All SNPs in FCER1B
and HNMT showed complete linkage disequilibrium (|D′ |=1
& r2≠1), and haplotype 1, 2 and 4 of FCER1B are equivalent
with FCER1B-109T>C, FCER1B E237G and FCER1B
RsaI_ex7 (T>C), respectively, and haplotype 1 and 3 of HNMT
are equivalent with HNMT 939A>G and T105I, respectively.
No significant differences were found in haplotype frequen-
cies and genotype distributions among the three groups with
the alternative model (Table 5).
DISCUSSION
We investigated 11 SNPs of the four candidate genes (in-
cluding FCER1B, HNMT, HRH1 and HRH2) that might
be associated with AIU pathogenesis. In the present study,
no significant differences were found in allele and genotype
Gene Haplotype
AIU 
(n=220)
Other 
drug 
allergy
(n=106)
NC
(n=198)
FCER1B Ht1 (T-G-A-T) 0.7 0.65 0.68 0.39 0.66
Ht2 (C-G-G-T) 0.11 0.12 0.15 0.74 0.23
Ht3 (C-A-A-T) 0.13 0.13 0.11 0.78 0.52
Ht4 (C-A-A-C) 0.06 0.09 0.05 0.2 0.68
Ht5 (T-G-A-C) 0 0 0.01
Ht6 (T-G-G-T) 0 0.01 0 NA
Ht7 (C-A-G-T) 0 0 0.01
HNMT Ht1 (C-A) 0.75 0.7 0.69 0.42 0.17
Ht2 (C-G) 0.21 0.27 0.26 0.79 0.19
Ht3 (T-G) 0.05 0.03 0.05 0.53 0.76
Table 4. Haplotype frequencies of FCER1B and HNMT
*Logistic regression analysis  was applied to control for age, sex atopy
as covariables. Rare alleles are given in bold. AIU, ASA-induced urticaria/
angioedema; NA, non applicable.
p value*
AIU & 
other
AIU & 
NC
Gene Haplotype Genotype AIU (n=110) NC (n=99)
Other drug 
allergy (n=53)
p value*
AIU & other AIU & NC
FCER1B Ht1 Ht1/Ht1 53 (48.2%) 22 (41.5%) 45 (45.5%)
Ht1/- 47 (42.7%) 25 (47.2%) 44 (44.4%) NS NS
-/- 10 (9.1%) 6 (11.3%) 10 (10.1%)
Ht2 Ht2/Ht2 1 (0.9%) 1 (1.9%) 1 (1.0%)
Ht2/- 23 (20.9%) 11 (20.8%) 28 (28.3%) NS NS
-/- 86 (78.2%) 41 (77.4%) 70 (70.7%)
Ht3 Ht3/Ht3 2 (1.8%) 2 (3.8%) 2 (2.0%)
Ht3/- 25 (22.7%) 10 (18.9%) 18 (18.2%) NS NS
-/- 83 (75.5%) 41 (77.4%) 79 (79.8%)
Ht4 Ht4/Ht4 2 (1.8%) 0 1 (1.0%)
Ht4/- 9 (8.2%) 9 (17.0%) 8 (8.1%) NS NS
-/- 99 (90.0%) 44 (83.0%) 90 (90.9%)
HNMT Ht2 Ht2/Ht2 5 (4.5%) 4 (7.5%) 8 (8.1%)
Ht2/- 2 (1.8%) 1 (1.9%) 3 (3.0%) NS NS
-/- 103 (93.6%) 48 (90.6%) 88 (88.9%)
Table 5. Genotype distributions of haplotypes of FCER1B and HNMT
*Each p value was calculated with co-dominant, dominant and recessive models. Logistic regression analysis was applied to control for age, sex atopy
as covariables. AIU, ASA-induced urticaria/angioedema; NS, non significant.frequencies of the SNPs and their haplotypes between the
study groups, which suggests that these gene polymorphisms
may not be related with the development of AIU phenotype
in a Korean population. 
The high affinity IgE receptor is responsible for initiating
allergic response. The binding of an allergen to the receptor-
bound IgE leads to mast cell activation and the release of his-
tamines, which are responsible for clinical manifestations of
urticaria (16). The receptor is a tetrametric complex composed
of an alpha, a beta, and two disulfide-linked gamma chains
(17). While the genes for the alpha and gamma subunits are
both located on human and mouse chromosome 1 (18), the
beta gene is located on 11q13 and spans about 10 kb and con-
tains 7 exons (19). Although polymorphisms of the FCER1B
gene has been reported to be associated with atopy, total serum
IgE level, bronchial hyperresponsiveness, asthma, and the
basophilic histamine-releasing activity of asthmatic patients
(8-11, 20), no previous study has been made of the association
between FCER1B gene polymorphisms and urticaria/angio-
edema. This study, therefore, is the first to investigate whether
no significant association is found between the FCER1B gene
polymorphism with the AIU phenotype in a Korean popula-
tion. Also, autoimmunity against the high affinity IgE recep-
tor has been reported in chronic urticaria and AIU (6, 7). How-
ever, in this study, we could not find any significant associa-
tions between the five known SNPs of the FCER1B gene and
their haplotypes and AIU phenotype. Further studies in a
larger cohort will be needed to confirm these negative results
in different ethnic populations.
Histamine is regarded as a leading mediator in acute or
chronic urticaria/angioedema and antihistamines are still the
main treatment for urticaria/angioedema (5). Histamine is
metabolized primarily by HNMT and diamine oxidase in
mammals and the effects of histamine are mediated by three
pharmacologically defined receptors termed H1 and H2 (5,
21). Large individual variations of HNMT activity is found
in human tissues. Preuss et al. (12) have demonstrated that
HNMT T105I (C>T) is associated with decreased levels of
HNMT enzymatic activity; consequently, the presence of the
314T allele would be expected to result in reduced histamine
metabolism. Yan et al. (22) also have shown that the frequency
of HNMT 314C>T in asthmatics (q=0.18) is significantly
higher than in controls (q=0.14, OR=0.9, p<0.01) in Cau-
casians. HRH1 mediates the pro-inflammatory actions in the
cytokine release and adhesion process (23, 24), while HRH2
suppresses the production of the Th1 inducing cytokine IL-
12, resulting in a shift of the Th1/Th2 balance toward Th2
dominance (25). Thus, HRH1 and HRH2 are considered to
contribute to the pathogenesis of various allergic diseases. Few
studies have been made of these genetic polymorphisms and
allergic diseases. Sasaki et al. (26) have shown that no signifi-
cant association exists between atopic asthma and polymor-
phisms of HRH1, HRH2, and HNMT genes in a Japanese
population. The same SNPs were screened in this study. Al-
though the frequencies of the SNPs were similar with those
of the Japanese study, no significant differences were found
among the study groups.
In conclusion, these results suggest a lack of associations
between FCER1B (-109T>C, RsaI_in2G>A, I181L, E237G,
RsaI_ex7T>C), HRH1 (-17C>T, D349A), HRH2 (543G>
A, 826C>T), and HNMT (T105I, 939A>G) gene polymor-
phisms and their haplotypes and the AIU phenotype in a
Korean population. 
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